Kaposi's Sarcoma

Panretin Capsules Demonstrate Positive Results In Two Phase II Trials

Published in Cancer Weekly, March 2nd, 1998

Ligand (LYE-gand) Pharmaceuticals Inc., San Diego, California, announced that analyses of two Phase II trials with Panretin Capsules in patients with AIDS-related Kaposi's sarcoma (KS) showed patient response rates of 38 percent and 37 percent.

The two studies were similar in design, with one conducted by the AIDS Malignancy Consortium (AMC) sponsored by the National Cancer Institute (NCI) and the other conducted directly by Ligand. Both were multicenter, open label studies designed to evaluate the safety and efficacy of Panretin Capsules in patients with AIDS-related KS.

"With positive results from these two studies, and a New Drug Application...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-03-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry